Shares of Novavax, Inc. (NVAX) are up almost 4% to $4.50 in pre-market trading Wednesday after the company was initiated with a ‘Buy’ rating at Citigroup (C). Currently there are 2 analysts that rate Novavax shares a ‘Strong Buy’ and 2 a ‘Buy’. No analysts rate it a ‘Sell’. The biopharmaceuticals company has a median Wall Street price target of $10.00 with a high target of $14.00.
Novavax, Inc. has a t-12 price/sales ratio of 35.30. EPS for the same period registers negative at (-$0.30). The Gaithersburg, Maryland-based firm has a market cap of $1.03 billion.
In the past 52 weeks, NVAX has traded between a low of $2.32 and a high of $6.95, which is almost 200% above that low price. Over the past week however, the stock has declined 2.25%. Ticker is up 87% y/y. Year-to-date equity has lost 15.23% of its value.
The chart below shows where the stock has traded over the last year, with the 50-day and 200-day moving averages included.
Novavax, Inc., is a clinical-stage biopharmaceutical company that develops and commercializes recombinant protein nanoparticle vaccines and adjuvants. The firm was founded in 1987.